Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)

NCT05116917 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT05116917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)
Lead sponsor
Herlev Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 5, 2021
Completion date
October 19, 2023
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer